Current Challenges in Treating Unresectable Hepatocellular Carcinoma
| Autor: | Jean-François Dufour |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | healthbook TIMES. Oncology Hematology, Vol 18, Iss 4 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2673-2106 2673-2092 |
| DOI: | 10.36000/HBT.OH.2023.18.127 |
| Popis: | For a decade, sorafenib was the only available treatment option for patients with unresectable hepatocellular carcinoma (HCC). The surge in systemic therapies for the treatment of HCC patients over the past five years resulted in significantly prolonged survival and improved quality of life. However, due to the lack of predictive biomarkers of treatment response, it has also introduced challenges in clinical decision-making. This article provides an overview of the complexities in the treatment of patients with HCC. PEER REVIEWED ARTICLE Peer reviewers: Dr Thibaud Kössler (Geneva University Hospitals, Geneva, Switzerland) Prof. Jörg Trojan (University Hospital Frankfurt, Frankfurt, Germany) Submitted: November 14, 2023 CEST; Accepted: December 07, 2023 CEST |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|